Novartis (NVS) Q3 Earnings: Stock To Beat Estimates Again?
Zacks Investment Research | Oct 19, 2016 09:52PM ET
Novartis AG (NYSE:NVS) is scheduled to report third-quarter 2016 results on Oct 25.
In the last reported quarter, it recorded a positive earnings surprise of 3.39%. Overall, Novartis has posted an average negative earnings surprise of 2.38% in the four trailing quarters. Let’s see how things are shaping up for this announcement.
Why a Likely Positive Surprise?
Our proven model shows that Novartis is likely to beat earnings because it has the right combination of two key ingredients.
Zacks ESP: The Earnings Surprise Prediction or Earnings ESP , which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, stands at +0.84%. This is very meaningful and a leading indicator of a likely positive earnings surprise for shares.
Zacks Rank: Novartis carries a Zacks Rank #3 (Hold). Note that stocks with a Zacks Rank #1 (Strong Buy), #2 (Buy) and #3 have a significantly higher chance of beating earnings. The sell-rated stocks (#4 or #5), on the other hand, should never be considered going into an earnings announcement, especially when the company is witnessing negative estimate revisions.
The combination of Novartis’ favorable Zacks Rank and positive ESP makes us reasonably confident of a positive earnings beat on Oct 25.
Factors to Impact the Quarter
Novartis operates under three segments: Innovative Medicines (Pharmaceuticals), Alcon and Sandoz (Generics). Although the company expects 2016 to be a transformative year, it has been facing challenging conditions over the past few quarters.
Innovative Medicines is expected to continue being impacted by generic competition due to the genericization of Gleevec/Glivec in the U.S. The company’s ophthalmologic division, Alcon, continues to face challenges due to a slowdown in cataract equipment placements and weak sales of intraocular lenses. Going forward, we expect these factors to dampen sales at the segment. On the other hand, Novartis’ generic arm, Sandoz, in its efforts to strengthen the biosimilars portfolio and pipeline, should offset weakness in Alcon.
Last quarter, the company’s heart failure drug, Entresto, obtained a strong Class I recommendation in both the U.S. and the EU as per the heart failure treatment guidelines. These guidelines establish Entresto as the standard of care for symptomatic patients with heart failure with reduced ejection fraction (HFrEF). The company’s decision to increase spending on Entresto to build a U.S. primary care field force and add incremental medical support will drive expenses in the third quarter. Entresto sales are expected to be approximately $200 million in 2016.
Get The News You Want
In the third quarter, unfavorable movements in foreign exchange rates are estimated to impact sales by 1% and earnings by 2%.
Meanwhile, investor focus should remain on the sales ramp-up of newly launched drugs Entresto, Glatopa and Cosentyx. Main growth drivers at the oncology segment will include Jakavi, Tasigna, Promacta/Revolade, Tafinlar+Mekinist and the improved formulation of Exjade. Multiple sclerosis drug, Gilenya, should also perform well.
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.